(Q35017838)

5 August 2017

1 reference

title

Combination therapy for combined dyslipidemia (English)

1 reference

5 August 2017

1 reference

Christie M. Ballantyne

series ordinal

2

object named as

Christie M Ballantyne

1 reference

5 August 2017

Antonios M Xydakis

1

1 reference

PubMed ID

12467937

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Cardiology

5 August 2017

1 reference

5 August 2017

90

1 reference

5 August 2017

10B

1 reference

5 August 2017

21K-29K

1 reference

Cholesterol reduction yields clinical benefit: impact of statin trials

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Low-density lipoproteins and risk for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

The antiatherogenic role of high-density lipoprotein cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

LDL physical and chemical properties in familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Defects of lipoprotein metabolism in familial combined hyperlipidaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

7 January 2021

Diabetic dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Insulin resistance and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Mechanism of action of fibrates on lipid and lipoprotein metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Regulation of lipid and lipoprotein metabolism by PPAR activators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Cerivastatin and reports of fatal rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Statin-fibrate combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Treatment of hyperlipidemia with combined niacin-statin regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Fluvastatin with and without niacin for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Hepatic toxicity of unmodified and time-release preparations of niacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

FDA adverse event reports on statin-associated rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

From Inuit to implementation: omega-3 fatty acids come of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Optimizing the pharmacology of statins: characteristics of rosuvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Novel approaches to lipid lowering: what is on the horizon?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

Plasma triglyceride and coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902968-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(02)02968-5

1 reference

5 August 2017

1 reference

PubMed ID

12467937